Mylan launches generic Benicar and Benicar HCT high BP tablets in US
Global pharmaceutical company Mylan has launched the hypertension tablets Benicar and Benicar HCT in the US.
Benicar and Benicar HCT are the first generic version of Olmesartan Medoxomil tablets of Daiichi Sankyo.
Dubbed as Benicar, Olmesartan Medoxomil would be available in doses of 5 mg, 20 mg and 40 mg.
On the other hand, Olmesartan Medoxomil Hydrochlorothiazide named as Benicar HCT would be available in doses of 20mg/12.5 mg, 40 mg/12.5 mg and 40 mg/25 mg.
Mylan’s Abbreviated New Drug Applications (ANDA) has got the final approval from US FDA for these products.
Olmesartan Medoxomil tablets are used in the treatment of hypertension in addition to other antihypertensive drugs for lowering blood pressure.
Mylan Pharmaceuticals
The combination drug, Olmesartan Medoxomil Hydrochlorthiazie is not recommended for initial therapy of hypertension, but is used in the latter stages to reduce hypertension.
According to IMS Health, Olmesartan Medoxomil tablets with doses 5 mg, 20 mg and 40 mg had approximately $1 billion US sales for the 12 months period ending August 31, 2016.
Olmesartan Medoxomil Hydrochlorothiazide with doses 20 mg/12.5 mg, 40 mg/12.5 mg and 40 mg/25 mg had registered $ 805 million in sales.
Mylan at present has 237 ANDAs that are pending for approval by FDA. As per IMS Health, these ANDAs represent $94.4 billion in annual brand sales.
Out of these 237 pending, 41 ANDAs are said to have the potential first-to-file opportunities representing $ 32.5 billion in annual brand sales for the 12 months ending June 30, 2016.
In general, hypertension drugs are contraindicated during pregnancy as they directly act on the Renin-Angiotensin System (RAA pathway) potentially causing injury and death to the developing fetus.
Mylan has more than 2700 generic and branded pharmaceuticals that include antiretroviral therapies. More than 50% of people who are getting treatment with HIV/AIDS depend on their drugs.
Mylan’s pharma products are marketed in more than 165 countries and include more than 50 facilities.
The pharma company is considered to be one of the world’s largest producers of API’s (Active Pharmaceutical ingredients).